All In Biotech

Drug Trial Radar · NCT00482833

Phase III Trial in Acute Promyelocytic Leukemia Patients

A Randomised Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA Versus Standard ATRA and Anthracycline-Based Chemotherapy (AIDA Regimen) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia

Last checked: Nov 20, 2026Latest source record: Oct 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 276 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

276

Actual

Start

Aug 2007

Primary completion

Sep 2012

Study completion Oct 17, 2019

Sponsor

Lead sponsor
Gruppo Italiano Malattie EMatologiche dell'AdultoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Study Alliance Leukemia (SAL) Group
First posted
Jun 5, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open label, randomised, phase III multicenter trial.

Conditions

  • Leukemia

Interventions

  • arsenic trioxideDrug

    Induction Arsenic Trioxide (As2O3=ATO), 0.15 mg/Kg IV over 2 hours daily starting on day 1. ATO will be continued until hematological CR or for a maximum of 60 days. Consolidation ATO, 0.15 mg/Kg IV over 2 hours daily for 5 days every week. Treatment will be continued for 4 weeks on and 4 weeks off, for a total of 4 cycles (last cycle administered on weeks 25 - 28).

  • idarubicinDrug

    Induction Idarubicin, 12 mg/m² on days 2, 4, 6 and 8 by short (20') intravenous infusion . If no hematological CR is achieved by 60 days after start of induction, patient will go off-study. Consolidation 1st cycle Idarubicin, 5 mg/m2/day by short (20') intravenous infusion on days 1, 2, 3, 4. 3rd cycle Idarubicin, 12 mg/m2/day as short (20') intravenous infusion only on day 1.

  • mercaptopurineDrug

    Maintenance therapy 6-Mercaptopurine (6-MP), 50 mg/m2/day orally. The dose will be adjusted according to hematopoietic toxicity during the follow-up period

  • methotrexateDrug

    Maintenance therapy Methotrexate (MTX), 15 mg/m2/weekly intramuscularly. The dose will be adjusted according to toxicity during the follow-up period.

  • all-trans retinoic acidDrug

    Induction ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological CR and for a maximum of 60 days. Consolidation 1. st cycle ATRA, 45 mg/m2/day, will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15. 2. nd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15. 3. rd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15. Maintenance therapy ATRA, 45 mg/m2/day orally, for 15 days every three months until a two year period is completed.

  • all-trans retinoic acid (ATRA)Drug

    Induction All-trans retinoic acid (ATRA), 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological complete remission (CR, see below for definition) or for a maximum of 60 days. Consolidation ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment. Treatment will be administered for 2 weeks on 2 weeks off and for a total of 7 cycles (last cycle administered on weeks 25 - 26).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survivalTime frame: At maximum 3.5 years from study entry

Locations

110 sites in 3 countries. Site status is shown where the registry gives one.

  • Universitätsklinik Innsbruck Hämatologie Onkologie

    Innsbruck, Austria

  • Krankenhaus der Barmherzigen Schwestern Linz

    Linz, Austria

  • Universitätsklinik für Innere Medizin III Salzburg

    Salzburg, Austria

  • Klinikum Bayreuth GmbH

    Bayreuth, Germany

  • Charité Campus Benjamin Franklin Berlin

    Berlin, Germany

  • Städt. Kliniken Bielefeld gem. GmbH

    Bielefeld, Germany

  • Universitätsklinikum Bonn

    Bonn, Germany

  • Ev. Diakonie-Krankenhaus gGmbH Bremen

    Bremen, Germany

  • Klinikum Bremen-Mitte gGmbH

    Bremen, Germany

  • Klinikum Chemnitz gGmbH

    Chemnitz, Germany

  • Universitätsklinikum C. G. Carus Dresden

    Dresden, Germany

  • Katholisches Klinikum Duisburg St. Johannes Hospital

    Duisburg, Germany

  • Universitätsklinikum Düsseldorf

    Düsseldorf, Germany

  • Uniklinikum Erlangen

    Erlangen, Germany

  • Kliniken Essen Süd, Ev. Krankenhaus Essen-Werden gGmbH

    Essen, Germany

  • Universitätsklinikum Essen

    Essen, Germany

  • Uniklinik Frankfurt/Main

    Frankfurt am Main, Germany

  • Städtische Kliniken Frankfurt a. M.-Höchst

    Frankfurt/a. M. -Höchst, Germany

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • Klinikum Fulda

    Fulda, Germany

  • Universitätsklinikum Gießen und Marburg Gießen

    Giessen, Germany

  • Universitätsklinikum Göttingen

    Göttingen, Germany

  • Asklepios Klinik Hamburg Altona

    Hamburg, Germany

  • Asklepios Klinik St. Georg Hamburg

    Hamburg, Germany

  • Universitätsklinikum Hamburg Eppendorf

    Hamburg, Germany

  • St. Marien-Hospital gem. GmbH Hamm

    Hamm, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Universitätsklinikum Heidelberg

    Heidelberg, Germany

  • St. Bernward Krankenhaus Hildesheim

    Hildesheim, Germany

  • Universitätsklinikum des Saarlandes Homburg/Saar

    Homburg, Germany

  • Klinik für Knochenmarktransplantation und Hämatologie Idar-Oberstein

    Idar-Oberstein, Germany

  • Westpfalz-Klinikum GmbH Kaiserslautern

    Kaiserslautern, Germany

  • Caritas-Krankenhaus Lebach

    Lebach, Germany

  • Klinikum Lippe Lemgo

    Lippe, Germany

  • Uniklinikum Lübeck

    Lübeck, Germany

  • Klinikum der Johannes Gutenberg Universität Mainz

    Mainz, Germany

  • Universitätsklinikum Gießen und Marburg GmbH Marburg

    Marburg, Germany

  • Carl-von-Basedow-Klinikum Merseburg

    Merseburg, Germany

  • Johannes Wesling Klinikum Minden

    Minden, Germany

  • Klinikum rechts der Isar (München)

    München, Germany

Showing 40 of 110 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.